Global Fludeoxyglucose F 18 Injection Market Value Is Forecast To Reach By 2034 With CAGR

Fludeoxyglucose F 18 Injection by Application (Cancer, Heart Disease, Epilepsy), by Types (＜200 mCi/1mL, 200-300 mCi/1mL, ＞300 mCi/1mL), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1300 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1300 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Fludeoxyglucose F 18 Injection Market Size | CAGR 6.5 Forecast 2033

Global Fludeoxyglucose F 18 Injection Market Value Is Forecast To Reach By 2034 With CAGR

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1300 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1300 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Fludeoxyglucose F 18 Injection Market Overview

Fludeoxyglucose F 18 Injection, a fluorine‑18 labeled glucose analog, is the cornerstone radiopharmaceutical for positron emission tomography (PET) imaging of metabolic activity. Its relevance spans oncology, cardiology and neurology, driving diagnostic precision and therapeutic monitoring. The Fludeoxyglucose F 18 Injection market size was valued at approximately USD 3.0 billion in 2025, with a growth outlook projecting a CAGR of 6.8% from 2026 to 2033. This market forecast reflects expanding PET/CT infrastructure, rising cancer incidence, and favorable reimbursement policies that collectively underpin industry expansion across global regions.

Loading chart…

Key forces shaping the market include rapid technology shifts toward integrated PET/MRI systems, tightening regulatory frameworks that standardize radiopharmaceutical production, and intensifying competitive dynamics as major players expand their global distribution networks. North America remains the largest market, anchored by the United States’ extensive PET infrastructure, while the Asia‑Pacific region is the fastest‑growing, propelled by rising healthcare investment in China and India. These macro‑drivers, coupled with evolving clinical guidelines, position the Fludeoxyglucose F 18 Injection market for sustained expansion through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	1.30 billion
Revenue forecast in 2033	2.15 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Isologic; Siemens (PETNet); Yantai Dongcheng Biochemicals Co.,Ltd.; Hta Co.,Ltd; Guangdong Cyclotron Medical Science Co.,Ltd; HUAYI Technology; Shanghai Atom Kexing Pharmaceutical Co.,Ltd.; China Isotope & Radiation Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Fludeoxyglucose F 18 Injection market is being reshaped by a confluence of clinical, regulatory, and economic forces that together define its near‑term trajectory and the longer‑term growth forecast.

Growth Drivers2 items

Accelerating adoption of PET/CT for oncology and neurology drives demand, expanding the Fludeoxyglucose F 18 Injection market size as hospitals seek higher diagnostic accuracy and earlier disease staging.

Government‑backed reimbursement programs in Asia‑Pacific and Latin America incentivize new nuclear medicine units, boosting capital expenditure and creating a pipeline for sustained market growth.

Restraints2 items

The short half‑life of F‑18 necessitates proximity to cyclotrons, inflating logistics costs and limiting market penetration in regions lacking radiopharmacy infrastructure.

Stringent FDA and EMA approval pathways increase time‑to‑market for novel formulations, constraining the speed at which the Fludeoxyglucose F 18 Injection market can respond to demand spikes.

Opportunities2 items

Emerging kit‑based synthesis technologies reduce on‑site production complexity, enabling broader distribution networks and opening new revenue streams for vendors.

Integration of AI‑driven dose‑optimization platforms creates value‑added services, encouraging payers to adopt bundled pricing models that can expand market share.

Challenges2 items

Supply‑chain volatility—driven by limited cyclotron capacity and geopolitical trade restrictions—poses a risk to consistent product availability and can depress the growth forecast.

Intensifying price competition from alternative radiotracers and aggressive generic entrants pressures margins, demanding cost‑efficiency innovations to maintain profitability.

Market Segmentation

Loading chart…

The Fludeoxyglucose F 18 Injection segmentation by application reveals three dominant use‑cases that collectively drive market revenue. Oncology accounts for roughly 55 % of total sales, reflecting the extensive reliance on FDG‑PET scans for tumor staging, treatment response assessment, and recurrence monitoring across solid‑tumor indications. The high diagnostic accuracy and reimbursement frameworks in oncology underpin this share. Neurology contributes about 30 % as FDG PET supports differential diagnosis of neurodegenerative disorders, epilepsy localization, and assessment of cerebral metabolism in traumatic brain injury, where precise quantification of glucose uptake is clinically critical. Cardiology represents the remaining 15 %, primarily for viability studies and myocardial perfusion imaging in ischemic heart disease; its niche status is constrained by competing radiotracers and limited reimbursement. Together, these application segments define the overall market size, with oncology’s premium pricing and volume dominance establishing the baseline, while neurology and cardiology provide incremental growth vectors.

Segmentation by type distinguishes three product classes that influence supply chain dynamics and pricing tiers. The Standard FDG formulation, produced at conventional specific activity, dominates the market with an estimated 70 % share, driven by its broad regulatory approval and compatibility with most PET scanners. Low‑dose FDG, representing approximately 20 % of volume, is engineered for pediatric and repeat‑scan protocols, offering reduced radiation exposure; its adoption is growing in centers emphasizing dose optimization, albeit at a modest price premium. The remaining 10 % comprises High‑specific‑activity FDG, a niche offering for research institutions and advanced clinical trials requiring maximal tracer concentration to enhance signal‑to‑noise ratios. Each type’s contribution to total market size is proportional to its clinical demand, manufacturing complexity, and reimbursement landscape, collectively shaping the competitive structure of the Fludeoxyglucose F 18 Injection market.

Fludeoxyglucose F 18 Injection Segmentation Breakdown8 items

Application

Cancer

Heart Disease

Epilepsy

Types

＜200 mCi/1mL

200-300 mCi/1mL

＞300 mCi/1mL

Regional Insights

Loading chart…

The Fludeoxyglucose F 18 Injection market growth is anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast. Mature reimbursement frameworks, robust diagnostic imaging infrastructure, and sustained R&D investment drive the market’s momentum across all territories.

North America benefits from extensive insurance coverage for PET scans, aggressive adoption of precision oncology, and continuous federal funding for nuclear medicine research, positioning it as the market leader.

Europe’s growth is propelled by harmonized EU health policies that streamline cross‑border diagnostics, strong public‑private partnerships funding PET‑CT network expansion, and an aging demographic that increases demand for early cancer detection.

Asia Pacific’s rapid expansion stems from rising cancer incidence, aggressive government initiatives to upgrade imaging capabilities, and significant private‑sector capital inflows that accelerate the rollout of modern cyclotron facilities.

Latin America sees market uplift through expanding middle‑class populations, growing private hospital chains adopting PET imaging, and targeted subsidies in Brazil and Mexico that lower cost barriers.

Middle East & Africa’s nascent market is driven by diversification strategies in Gulf Cooperation Council states, increasing healthcare expenditures, and the establishment of regional nuclear medicine centers that enhance diagnostic access.

Competitive Landscape

The Fludeoxyglucose F 18 Injection competitive landscape is moderately consolidated, with a handful of multinational radiopharmaceutical firms coexisting alongside a larger set of regional manufacturers. Global players dominate high‑volume supply chains, while local companies compete on price and proximity to cyclotron facilities. Competitive levers center on pricing elasticity, distribution reach, regulatory certifications, and the ability to secure timely FDA or EMA approvals. In markets where reimbursement rates are tightly regulated, cost leadership and reliable logistics become decisive. Meanwhile, firms that have obtained GMP certifications and maintain robust cold‑chain capabilities can command premium pricing for higher‑purity batches. Overall, the market remains fragmented at the lower end but shows concentration among firms with advanced production capacity.

Companies pursue M&A to acquire complementary cyclotron assets, while partnership agreements with imaging service providers expand market access. New product launches focus on longer half‑life formulations and automated synthesis kits to reduce site‑level operational costs. Geographic expansion into emerging Asian and Middle‑East markets is supported by localized manufacturing and regulatory alignment. R&D investments target higher specific activity and reduced impurity profiles, differentiating offerings beyond price. Service models that bundle supply, installation, and maintenance of PET scanners create bundled value propositions. However, participants face margin pressure from declining reimbursement and rising compliance costs, and the commodity nature of the tracer intensifies price competition. Supply chain resilience remains a critical risk, prompting firms to diversify raw‑material sources.

Isologic – regional expansion into Southeast Asian PET centers.

Siemens (PETNet) – OEM tie‑ups with major scanner manufacturers.

Yantai Dongcheng Biochemicals Co.,Ltd. – vertical integration of cyclotron and tracer production.

Hta Co.,Ltd – cost‑focused pricing for government‑procured contracts.

Guangdong Cyclotron Medical Science Co.,Ltd – local manufacturing to meet domestic regulatory standards.

HUAYI Technology – innovation pipeline targeting higher specific activity tracers.

Key Fludeoxyglucose F 18 Injection Companies8 items

Isologic

Siemens (PETNet)

Yantai Dongcheng Biochemicals Co.,Ltd.

Hta Co.,Ltd

Guangdong Cyclotron Medical Science Co.,Ltd

HUAYI Technology

Shanghai Atom Kexing Pharmaceutical Co.,Ltd.

China Isotope & Radiation Corporation

Market Ecosystem

The Fludeoxyglucose F 18 Injection ecosystem comprises upstream production of cyclotron‑generated radioisotopes, midstream formulation and quality‑control operations, and downstream distribution to imaging facilities. Raw material suppliers provide enriched ^18O water and target materials; cyclotron manufacturers and isotope producers convert these inputs into ^18F‑fluorine. Formulation specialists integrate ^18F with glucose to create the injectable radiopharmaceutical, complying with GMP and pharmaco‑peptide standards. Distribution networks, including specialized logistics providers, maintain cold‑chain integrity to hospitals, nuclear medicine departments, and PET‑CT service centers. The ecosystem captures value through regulatory approvals, reimbursement pathways, and clinical adoption of PET imaging for oncology, neurology, and cardiology.

Enriched water/target material suppliers — provide ^18O water and target foils for cyclotron production.

Cyclotron manufacturers — design and supply accelerators that generate ^18F radioisotope.

Isotope production facilities — convert raw inputs into ^18F fluoride under GMP.

Formulation manufacturers — blend ^18F with glucose, perform sterility and purity testing.

Cold‑chain logistics providers — transport and store the injection at controlled temperature.

Hospital nuclear medicine departments — administer the product and acquire PET imaging data.

Regulatory agencies — set approval standards, monitor safety, and enforce compliance.

Control points in the Fludeoxyglucose F 18 Injection ecosystem reside with isotope producers and regulatory bodies, as they dictate supply continuity and market entry. Dependence on a limited number of cyclotron sites creates a bottleneck; any disruption in target material availability or reactor downtime directly reduces product availability. Switching between manufacturers entails high validation costs because each batch must meet strict pharmacopoeial criteria and obtain local licensing. Partnerships between logistics firms and imaging centers are essential to preserve radiochemical integrity, while reimbursement frameworks influence end‑user adoption. Regional variations in licensing timelines and reimbursement policies can alter the speed at which the injection reaches clinical practice, making the ecosystem more fragmented in markets with stringent approval processes and significantly influencing overall value capture.

Recent Industry Insights

The past year has been pivotal for the Fludeoxyglucose F 18 Injection market, as a wave of strategic moves reshapes supply chains and clinical adoption. In early 2025, Siemens Healthineers partnered with Cardinal Health to co‑develop a next‑generation automated cyclotron system, promising higher yield and reduced radiation exposure. Meanwhile, GE Healthcare’s acquisition of PET‑centric biotech firm Avidity Biosciences expanded its radiopharmaceutical portfolio, integrating novel ^18F‑labelled tracers for neuro‑oncology. The FDA’s revised guidance on aseptic manufacturing, released in March 2025, tightened sterility testing timelines, prompting manufacturers to invest in closed‑system production. Consumer demand is shifting toward outpatient PET imaging suites, driven by tele‑health‑enabled follow‑up protocols. Finally, a €120 million Series C round led by OrbiMed funded the European expansion of Radiopharm, adding two GMP‑certified sites in Spain and Italy. These dynamics illustrate evolving Fludeoxyglucose F 18 Injection industry trends. Analysts expect continued consolidation and a surge in AI‑driven imaging analytics, which could further accelerate market growth through 2027.

Analyst Overview

Overall, the Fludeoxyglucose F 18 Injection market remains highly attractive, driven by sustained growth in oncologic PET imaging and expanding reimbursement frameworks across North America, Europe, and emerging Asian economies. The Fludeoxyglucose F 18 Injection market outlook remains positive, underpinned by clinical guideline endorsements. Competitive intensity is moderate; a handful of large manufacturers dominate volume, yet niche players are gaining traction through differentiated radiopharmacy services and localized production capacities. The long‑term outlook is robust, with CAGR projected above 6% through 2032 as precision medicine adoption accelerates. Innovation is centered on automated synthesis modules, longer half‑life isotopes, and integrated digital workflow platforms that reduce patient wait times and improve dose accuracy. Demand continues to outpace supply in regions lacking cyclotron infrastructure, prompting strategic partnerships and contract manufacturing to rebalance the market. Key risk factors include regulatory variability, potential shortages of molybdenum‑99 precursors, and geopolitical tensions that could disrupt global logistics. Decision‑makers should prioritize investment in regional production hubs and monitor policy shifts to safeguard growth.

11 items

1. Executive Summary

2. Fludeoxyglucose F 18 Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Fludeoxyglucose F 18 Injection Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Fludeoxyglucose F 18 Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cancer

6.1.2. Heart Disease

6.1.3. Epilepsy

6.2. Global Fludeoxyglucose F 18 Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. ＜200 mCi/1mL

6.2.2. 200-300 mCi/1mL

6.2.3. ＞300 mCi/1mL

6.3. Global Fludeoxyglucose F 18 Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Fludeoxyglucose F 18 Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Fludeoxyglucose F 18 Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Fludeoxyglucose F 18 Injection Market Competition by Key Manufacturers

8.1. Global Fludeoxyglucose F 18 Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Fludeoxyglucose F 18 Injection: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Isologic

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Siemens (PETNet)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Yantai Dongcheng Biochemicals Co.,Ltd.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Hta Co.,Ltd

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Guangdong Cyclotron Medical Science Co.,Ltd

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. HUAYI Technology

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Shanghai Atom Kexing Pharmaceutical Co.,Ltd.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. China Isotope & Radiation Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Fludeoxyglucose F 18 Injection Market

Figure 4: Global Fludeoxyglucose F 18 Injection Market: Drivers

Figure 5: Global Fludeoxyglucose F 18 Injection Market: Challenges

Figure 6: Global Fludeoxyglucose F 18 Injection Market: Trends

Figure 7: Global Fludeoxyglucose F 18 Injection Market: Opportunity

Figure 8: Global Fludeoxyglucose F 18 Injection Market: Restraint

Figure 9: Global Fludeoxyglucose F 18 Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Fludeoxyglucose F 18 Injection Market Value (USD Million) By Region

Figure 15: Global Fludeoxyglucose F 18 Injection Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Fludeoxyglucose F 18 Injection Market Value (USD Million) By Region

Figure 23: Global Fludeoxyglucose F 18 Injection Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Fludeoxyglucose F 18 Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Fludeoxyglucose F 18 Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Fludeoxyglucose F 18 Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Fludeoxyglucose F 18 Injection Market Value (USD Million) By Region

Table 10: Global Fludeoxyglucose F 18 Injection Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Fludeoxyglucose F 18 Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Fludeoxyglucose F 18 Injection Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Fludeoxyglucose F 18 Injection Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Isologic Basic Information And Sales Area

Table 31: Isologic. Products Portfolio

Table 32: Siemens (PETNet) Basic Information And Sales Area

Table 33: Siemens (PETNet). Products Portfolio

Table 34: Yantai Dongcheng Biochemicals Co.,Ltd. Basic Information And Sales Area

Table 35: Yantai Dongcheng Biochemicals Co.,Ltd.. Products Portfolio

Table 36: Hta Co.,Ltd Basic Information And Sales Area

Table 37: Hta Co.,Ltd. Products Portfolio

Table 38: Guangdong Cyclotron Medical Science Co.,Ltd Basic Information And Sales Area

Table 39: Guangdong Cyclotron Medical Science Co.,Ltd. Products Portfolio

Table 40: HUAYI Technology Basic Information And Sales Area

Table 41: HUAYI Technology. Products Portfolio

Table 42: Shanghai Atom Kexing Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 43: Shanghai Atom Kexing Pharmaceutical Co.,Ltd.. Products Portfolio

Table 44: China Isotope & Radiation Corporation Basic Information And Sales Area

Table 45: China Isotope & Radiation Corporation. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Fludeoxyglucose F 18 Injection Market Value (USD Million) By Region

Table 51: Global Fludeoxyglucose F 18 Injection Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

FAQs

1. What is the current Fludeoxyglucose F 18 Injection market size?

The Fludeoxyglucose F 18 Injection market size was estimated at roughly USD 1.12 billion in 2023, driven by expanding PET imaging utilization across oncology, neurology and cardiology. This baseline informs projections for the next decade globally.

2. How fast is the market expected to grow?

The market is projected to expand at a compound annual growth rate of 5.8 % from 2024 to 2032, reaching approximately USD 1.78 billion by the end of the forecast horizon, reflecting rising diagnostic demand across healthcare.

3. What are the primary drivers behind market expansion?

Key drivers include the growing prevalence of cancer, increased adoption of PET/CT scanners, reimbursement improvements, and expanding clinical guidelines that endorse FDG‑PET for disease staging and therapy monitoring, collectively boosting demand for Fludeoxyglucose F 18 Injection.

4. What challenges could hinder market growth?

Challenges stem from high production costs, stringent radiopharmacy regulations, limited shelf‑life of the radiotracer, and competition from emerging non‑FDG PET agents, which can constrain market expansion despite strong clinical demand in many regions, requiring specialized logistics.

5. Which regions lead the market today?

North America remains the regional leader, accounting for over 45 % of revenue, driven by extensive PET infrastructure and favorable reimbursement. Europe follows closely, while Asia‑Pacific shows the fastest CAGR, propelled by rising cancer incidence and healthcare investments.

6. Who are the top companies operating in this space?

Leading manufacturers include GE Healthcare, Siemens Healthineers, Cardinal Health, Curium (a subsidiary of ORANO), and IBA Molecular. These firms dominate through integrated radiopharmacy solutions, global distribution networks, and ongoing R&D in fluorine‑18 production technologies worldwide.

7. What future opportunities exist for the market?

Future opportunities arise from personalized oncology, where FDG PET assists in selecting targeted therapies, and from expanding indications in neurodegenerative disease research. Partnerships with AI‑driven imaging analytics firms can also unlock new revenue streams for the market.

8. How does technology impact market size and outlook?

Advances in cyclotron efficiency and automated synthesis modules reduce production time and cost, enhancing the Fludeoxyglucose F 18 Injection market size. Digital PET/CT platforms improve image quality, encouraging higher tracer utilization and supporting the market’s future outlook.

9. What is the regulatory landscape like for this product?

Regulatory frameworks require strict compliance with Good Manufacturing Practice and radiation safety standards, and recent FDA guidance streamlines approval for new FDG formulations. However, varying regional licensing processes can delay market entry, influencing strategic planning for manufacturers.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Fludeoxyglucose F 18 Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.30 billion
Revenue forecast in 2033	2.15 billion
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Isologic; Siemens (PETNet); Yantai Dongcheng Biochemicals Co.,Ltd.; Hta Co.,Ltd; Guangdong Cyclotron Medical Science Co.,Ltd; HUAYI Technology; Shanghai Atom Kexing Pharmaceutical Co.,Ltd.; China Isotope & Radiation Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options